Introduction
Chronic obstructive pulmonary disease (COPD) and lung cancer remain major public concerns due to the increased morbidity and mortality with which they are globally associated (1, 2) . COPD is a risk factor for lung cancer, and studies into associations between COPD and lung cancer have suggested strategies for decreasing the burden of the conditions (3) . Smoking tobacco is a leading cause of COPD (4) (5) (6) (7) . However, only a small proportion of smokers develop COPD, and only a subsection of all patients with COPD develop lung cancer (3) . Therefore, host differences serve important functions in the pathogenesis of these diseases. The present study hypothesized that environmental risk factors and a genetic predisposition may facilitate the development of COPD and concurrent lung cancer. Genome-wide association studies have provided statistically significant associations between COPD and multiple gene variants that may function in its pathogenesis (8) (9) (10) . Therefore, improved understanding of the genetic background of COPD and of COPD with lung cancer is crucial to uncovering the pathogenic mechanisms of, and developing novel therapeutic strategies for, these diseases.
Macrophages serve a key function in defending against respiratory infections. Macrophage scavenger receptors (MSRs) are located on the surface of alveolar macrophages and are associated with a range of functions, including phagocytosis, antigen presentation, apoptotic cell clearance and bacterial and particle uptake (11, 12) . A decreased ability of alveolar macrophages to phagocytose apoptotic cells and bacteria results in inflammation, which exacerbates COPD (13) . Hirayama et al (14) demonstrated that a scavenger receptor was also an independent prognostic factor in lung squamous cell carcinoma, and that it may generate tumor-promoting microenvironments. Therefore, MSR1 may serve a function in COPD and in COPD with lung cancer.
MSR1 is located on chromosome 8p22 and is composed of 11 exons (15). Bossé et al (8) provided an overview of genes associated with COPD, including MSR1. Seven missense mutations or sequence variants (ex3P36A_C>G, ex3S41Y_ C>A, ex4V113A_T>C, ex4P174Y_G>T, ex6P275A_C>G, ex10G369S_G>A, and ex11H441R_A>G) and one nonsense mutation at codon 293 (ex6R293x_C>T) have been reported to serve an important role in the structure and function of MSR1 (16). A previous study revealed that a coding single-nucleotide polymorphism (SNP; ex6P275A_C>G) of MSR1 was associated with COPD susceptibility, COPD-associated measures of lung function and abnormalities (10) . To the best of our knowledge, there have been no studies evaluating the association between MSR1 variants and COPD with lung cancer susceptibility. In the present study, the association between the variants of MSR1 and COPD with or without lung cancer in China was assessed.
Materials and methods
Patients. From 1 July 2015 to 20 February 2016, 100 patients with COPD with lung cancer, 100 patients with COPD without lung cancer and 100 healthy smokers were enrolled at the Department of Pulmonary & Critical Care Medicine, Shanghai Institute of Respiratory Disease, Shanghai Ruijin Hospital Affiliated to the School of Medicine, Shanghai Jiao Tong University (Shanghai, China). The age of patients with COPD, patients with COPD with lung cancer subjects and healthy smokers was 68.33±6.47 years, 65.79±7.77 years and 66.47±9.67 years (data are presented as mean ± standard deviation), respectively, and the male distribution of the three groups was 76, 79 and 72%, respectively. COPD was diagnosed according to the criteria proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (17) . Lung carcinoma was diagnosed by pathological examination by Dr. Yuan (Department of Pathology, Shanghai Ruijin Hospital Affiliated to the School of Medicine, Shanghai Jiao Tong University). Any patient with a history of bronchial asthma, diabetes, hypertension or any other associated pulmonary disease was excluded from the study. The healthy controls exhibited normal lung function without any history of COPD, cancer, asthma or any other pulmonary infectious diseases. The healthy smokers were recruited when they attended the Ruijin Hospital for medical tests from July 2015 to February 2016. The healthy controls were age-, sex-and cigarette packs smoked/year-matched for patients with COPD with and without lung cancer. In the present study, the phenotypes of COPD based on the computed tomography (CT) imaging of the chest were divided into 3 types: Emphysema, airway obstruction (airway) and mixed type (hybrid). In patients with COPD without lung cancer, 21% exhibited an emphysema phenotype, 12% exhibited airway phenotype and the rest exhibited a hybrid phenotype. In patients with COPD with lung cancer, 30% exhibited an emphysema phenotype, 4% exhibited an airway phenotype and the rest exhibited a hybrid phenotype. All patients who participated in the present study provided written informed consent. The protocol was reviewed and approved by the Ruijin Hospital Ethics Committee of Shanghai Jiao Tong University, School of Medicine.
Lung function evaluation. Lung function tests were performed using a MasterScreen™ spirometry machine (BD Biosciences, Franklin Lakes, NJ, USA) 20 min prior to and after inhaling 400 µg salbutamol (GlaxoSmithKline, Plc., Brentford, UK) Forced expiratory volume in 1 sec (FEV 1 ) and forced vital capacity (FVC) were measured. The patients were instructed to take the deepest breath they could and then exhale with maximum intensity into the spirometry machine for at least 6 sec. The bronchial dilation test was performed after the patients had inhaled 400 µg salbutamol. Short-acting inhaled drugs were not administered during the 12 h prior to testing. Long-acting bronchodilator therapy was ceased for 24 h prior to testing. Theophylline sustained-release tablets and atropine were not administered for 24 and 8 h, respectively, prior to spirometry. The present study was not a long term experiment for one subject. Blood was drawn and the lung function test was performed when patients were enrolled. The short-acting inhaled drugs, long-acting bronchodilator therapy, theophylline sustained-release tablets and atropine were not used during the study to avoid any effects of the medicine on the lung function tests. All pulmonary function tests were performed according to the GOLD criteria (18) .
DNA extraction and genotyping. Genomic DNA was extracted from patient whole blood containing EDTA using a DNeasy Blood & Tissue kit (cat. no. 69506; Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocol, and stored at -20˚C until use. The genomic DNA underwent polymerase chain reaction (PCR) in a 50 µl reaction mixture (2xTaq PCR Master mix, cat. no. KT201; Tiangen Biotech Co., Ltd., Beijing, China). The template was replaced with DEPC water (Invitrogen; Thermo Fisher Scientific, Inc.) for use as the negative control. The details of the primers are summarized in Table I . The PCR reactions consisted of 35 cycles of 30 sec at 95˚C, 30 sec at 55˚C and 1 min at 72˚C. A total of 200 patients and 100 healthy controls were tested for eight SNPs (ex3P36A_C/G, ex3S41Y_C/A, ex4V113A_T/C, ex4P174Y_G/T, ex6P275A_C/G, ex6R293x_C/T, ex10G369S_G/A and ex11H441R_A/G) in the 5 exonic regions of the MSR1 gene (Table I ). Due to the primer design, the size of the PCR products was increased compared with that of the exon. Therefore, variants in the adjacent intron, including rs13306550, were observed.
Statistical analysis. The distribution of age, sex and smoking pack/year of patients with COPD with or without lung cancer and healthy smokers all conformed to the law of normal distribution. Data were expressed as the mean ± standard deviation. Data regarding the lung function and the COPD Assessment Test (CAT) score did not conform to the normal distribution; these were expressed as the median (Q 3 -Q 1 ). The Mann-Whitney U test was used to analyze the difference in lung function tests and CAT scores between patients with COPD with and without rs13306550. An exact test was used to assess the variation in SNP rs13306550 from the Hardy-Weinberg equilibrium in all three groups (P>0.05). Data on the age, sex and smoking pack/year between the three groups were assessed using a one-way analysis of variance with Student-Newman-Keuls test performed as a post-hoc test. The and the variation of each SNP was assessed using Fisher's exact tests. For all tests, two-sided P-values of <0.05 were considered to indicate a statistically significant difference. All data were analyzed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Each assay was performed in triplicate and independently repeated at least 3 times.
Results
Study patients. A total of 300 patients were enrolled in the present study. The characteristics of all patients are listed in Table II . Among the 100 patients with COPD, the mean age was 68.33±6.47 and 76% were male. All patients with COPD were diagnosed according to the GOLD criteria (17) . The patients with COPD smoked a mean pack/year of 45.59±32.34. CT scanning serves a notable role in the identification of the different phenotypes of COPD. Although a majority of patients with COPD have some form of overlap between airway morphologic changes and parenchymal destruction, it is relatively easy to differentiate between those having an emphysema predominant disease and those presenting with predominant airway abnormalities. As a result, in this study, the types of COPD based on the computed tomography imaging of the chest have been divided into 3 types: Emphysema; airway obstruction (airway); and mixed type (hybrid) as reported by Grenier et al (19) . The phenotype of the patients with COPD included emphysema (21%), airway (12%) and hybrid (67%). Among the 100 patients with COPD with lung cancer, the mean age was 65.79±7.77 and 79% were male. The phenotype of these patients included emphysema (30%), airway (4%) and hybrid (66%). These patients smoked a mean pack/year of 44.94±20.86; 12% of these patients developed concurrent small cell lung cancer, 39% with squamous carcinoma and 49% with adenocarcinoma. The mean age of the healthy smokers was 66.47±9.67 and 72% were male. The healthy smokers smoked a mean pack/year of 38.13±19.08.
MSR1 exon variants is associated with risk of COPD with/without lung cancer.
In the present study, eight SNPs (ex3P36A_C>G, ex3S41Y_C>A, ex4V113A_T>C, ex4P174Y_ G>T, ex6P275A_C>G, ex6R293x_C>T, ex10G369S_G>A and ex11H441R_A>G) were genotyped in 300 patients, including 100 healthy smokers, 100 patients with COPD without lung cancer and 100 patients with COPD with lung cancer (Table III) .
The genotype frequencies of these eight variants did not significantly differ among the three groups. It was identified that the SNP rs13306550 is significantly associated with an increased risk of COPD. However, no significant difference in the distribution of the SNP rs13306550 was demonstrated between those COPD patients with and without lung cancer (P=0.51; Table IV ). Of the patients with COPD, 10% had heterozygous mutations of rs13306550 (Fig. 1A) ; 13% of patients with COPD with lung cancer were positive for this variant, all of which were the heterozygous mutation (Fig. 1A) . The genotyping results of patients without this polymorphism are presented in Fig. 1B. A significant difference in the distribution of SNP rs11306550 was identified between patients with COPD with lung cancer and the healthy controls, but not the patients with COPD (Table IV) . For the patients with COPD without lung cancer and the controls, and the patients with COPD with lung cancer and the controls, the odds ratio was >1, which suggested that the rs13306550 SNP is a harmful factor for COPD morbidity. This SNP is associated with an increased susceptibility of COPD, and smokers with rs13306550 tend to develop COPD more easily compared with those without the SNP. However, there is no evidence about this polymorphism suggesting that it may contribute to the pathogenesis of lung cancer in patients with COPD. Rs13306550 SNP is not significantly associated with COPD severity. To assess whether SNP rs13306550 serves a crucial function in COPD severity, the results of lung function tests and the CAT score were analyzed between the patients with COPD with and without this SNP. Data regarding lung function and the CAT score did not conform to the normal distribution and thus were expressed as the median (Q 3 -Q 1 ). The Mann-Whitney U test was used to analyze the data. The results indicated no significant difference in lung function between patients with COPD with and without the SNP rs13306550 (Table V) . The results of FEV 1 /FVC, FEV 1 % predicted and the CAT scores between the patients and the controls did not significantly differ.
Discussion
To evaluate the association between MSR1 variants and the risk of COPD with and without lung cancer, seven missense mutations (Pro36Ala, Ser41Tyr, Val113Ala, Asp174Tyr, CC  100  100  100  ex4V113A  TT  100  100  100  ex4P174Y  GG  100  100  100  rs13306550  AA  90  87  99  AG  10  13  1  GG  0  0  0  ex6P275A  CC  98  100  99  CG  2  0  1  GG  0  0  0  ex6R293ⅹ  CC  100  100  100  ex10G369S  GG  100  100  100  ex11H441R AA 100 100 100
Data are adjusted for sex, age and smoking. CA, lung cancer; COPD, chronic obstructive pulmonary disease; SNP, single-nucleotide polymorphism. Pro275Ala, Gly369Ser and His441Arg) and one nonsense mutation at codon 293 (Arg293X), which serve an important role in the function and structure of MSR1, were identified (16). The SNP P275A is associated with COPD susceptibility in smokers, as indicated through the results of the spirometry tests. For the quantitative lung function measures analyzed using spirometry in the total population of smokers, subjects with the CG genotype at P275A exhibited a significantly lower FEF 25-75 compared with the CC subjects (P=0.03) (10, 20) . However, these results are inconsistent with those of the present study. In the present study, 100 patients with COPD with lung cancer, 100 patients with COPD without lung cancer and 100 healthy controls were genotyped. The results revealed no significant association between the eight aforementioned variants and COPD risk, which were inconsistent with the studies performed by Ohar et al (10) and Ben et al (20) . The heterogeneity observed in these previous studies may be due to the genetic background and sample size.
Although no significant association with regard to these eight variants was observed, the SNP rs13306550 was demonstrated Table IV . Association of the macrophage scavenger receptor 1 gene polymorphism rs13306550 with the risk of COPD and coexistence of COPD and lung cancer.
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Healthy controls COPD (N=100) to be associated with COPD morbidity. Of the patients with COPD, 10% tested positive for the variant, while only one of the healthy controls was positive for it. Furthermore, 13% of the patients with COPD and lung cancer tested positive for the variant but no significant difference was identified between patients with COPD with and without lung cancer. That this polymorphism is associated with COPD susceptibility, but does not influence the pathogenesis of lung cancer in patients with COPD, could explain the results obtained.
Scavenger receptors on alveolar macrophages are crucial for identifying and eliminating airborne microorganisms and inhaled particles (21) . Irritants, including cigarette smoke, may activate macrophages, resulting in inflammation through the release of neutrophil, monocyte, and T-lymphocyte chemotactic factors (22) . Multiple mechanisms, including infection, apoptosis and oxidative stress characterize COPD pathogenesis (23) . In innate immunity, alveolar macrophages represent the initial line of host immune defenses responsible for the reactions that cigarette smoke may activate. Alveolar macrophages are also associated with cytokine secretion (24, 25) . These functional responses result in chronic inflammatory conditions and tissue destruction, which may enhance the emphysema commonly observed in patients with COPD (26-28). Kaku et al (29) revealed that MSR1 was overexpressed in patients with COPD and may be associated with COPD pathogenesis.
It was reported that MSR1 expression is decreased in tumor tissues compared with in normal tissues, and that this decreased MSR1 expression enhanced the growth and angiogenesis of lung carcinoma in mice (20) . Therefore, the overexpression of MSR1 in patients with COPD may not induce lung cancer pathogenesis and the SNP rs13306550 may not influence lung cancer susceptibility in patients with COPD.
The present study confirmed the location of the SNP rs13306550 in MSR1. Rs13306550 (IVS4+3A) is located in the splice donor site of exon 4 of MSR1 (30) . During evolution, splice donor sites and splice acceptor sites are commonly conserved. Mutations at the aforementioned splice site have been revealed to be associated with multiple genetic disorders (31) . The creation of pseudo-exons within introns, intron retention, exon skipping and the activation of cryptic splice sites result from abnormal pre-mRNA splicing, which usually results from splice site mutations (32) . In the present study, the distribution frequencies of the SNP rs13306550 differed significantly between the patients and the controls. Considering the location of this variant, it may be associated with COPD susceptibility.
As aforementioned, MSR1 is a macrophage scavenger receptor that identifies and clears potential pathogens during COPD exacerbation, including inhaled particles and microorganisms, modified lipids and apoptotic cells (33, 34) . Therefore, MSR1 is associated with the pathogenesis and exacerbation of COPD. However, no significant association was identified between the SNP rs13306550 and the lung function test outcomes or the CAT scores. Therefore, this variant may influence only COPD pathogenesis and not its exacerbation. However, the small sample size renders conclusions regarding the function of the rs13306550 SNP challenging.
To conclude, the present study demonstrated that the SNP rs13306550 represented a risk factor for COPD susceptibility, but does not influence lung cancer pathogenesis in patients with COPD. However, the mechanisms underlying how this variant influences the development and progression of COPD remain to be fully understood and require further study.
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